A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of the virus. A booster dose one year after the initial shot failed to do ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.